We offer a variety of development services for high-potency compounds in solid, semi-solid, and liquid dosage forms, including fast dissolve and controlled release tablets, nasal sprays, and Liquid-Filled Hard Capsules (LFHC). Patheon also offers the development of high-potency products in sterile dosage forms.

Our Pharmaceutical Development Services (PDS) scientists offer expertise in formulation development, Clinical Trial Materials (CTM) manufacturing, and scale-up of high-potency products, all comprehensively supported with an extensive range of in-house analytical services. Patheon has experience in developing compounds with Occupational Exposure Limits (OEL) in the low nanogram per cubic meter range.

Scientists and technical teams at Patheon are highly proficient in the safe handling of high-potency products. Our high-potency development programs utilize suites designed to meet the challenges of high-potency formulation development and manufacturing. At Toronto Region Operations (TRO) our skilled development scientists use a focused development facility that includes eight pilot scale development suites, two laboratories and dedicated dispensing and receiving areas to advance your high-potency compound through development. With a full range of laboratory scale equipment and isolator technology, Patheon’s TRO site can formulate high-potency products in a variety of dosage forms.

Patheon’s Center of Excellence in high-potency development is located in PDS Toronto Canada. Patheon’s Swindon Operations site in the UK can develop high-potency products in both conventional solid, semi-solid and liquid formats as well as sterile product formulations. These facilities can offer fully integrated development, scale-up and commercial manufacturing all in one site.

Click here to learn more about Patheon’s high-potency commercial manufacturing capabilities.